海利生物(603718) - 2023 Q1 - 季度财报
HILEHILE(SH:603718)2023-04-27 16:00

Financial Performance - The company's operating revenue for Q1 2023 was ¥71,234,419.78, representing a decrease of 16.27% compared to the same period last year[4] - Net profit attributable to shareholders was ¥14,235,681.29, an increase of 34.35% year-on-year[4] - Basic earnings per share were ¥0.022, reflecting a growth of 34.35% year-on-year[4] - Net profit for Q1 2023 reached CNY 13,593,233.44, an increase of 20.6% from CNY 11,252,852.09 in Q1 2022[19] - The total comprehensive income attributable to the parent company for Q1 2023 was CNY 17,276,441.29, compared to CNY 6,141,464.08 in Q1 2022, representing an increase of approximately 180.5%[20] Cash Flow - The net cash flow from operating activities was -¥35,585,211.73, showing an increase in outflow of 30.65% compared to the previous year[4] - The net cash flow from operating activities for Q1 2023 was -CNY 35,585,211.73, an improvement from -CNY 51,314,739.29 in Q1 2022[22] - Cash inflow from operating activities totaled CNY 72,324,888.22 in Q1 2023, up from CNY 51,388,620.38 in Q1 2022, marking a growth of approximately 40.6%[22] - The company reported cash outflows from operating activities of CNY 107,910,099.95 in Q1 2023, slightly higher than CNY 102,703,359.67 in Q1 2022[22] - Investment activities generated a net cash flow of -CNY 42,177,186.39 in Q1 2023, an improvement from -CNY 60,197,781.91 in Q1 2022[22] - The company experienced a net decrease in cash and cash equivalents of -CNY 77,886,303.86 in Q1 2023, an improvement from -CNY 91,684,562.37 in Q1 2022[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,468,797,288.51, a decrease of 3.00% from the end of the previous year[5] - The company's total assets as of March 31, 2023, were CNY 1,468,797,288.51, a decrease from CNY 1,514,252,528.46 at the end of 2022[14] - Current assets totaled CNY 612,482,085.63, down from CNY 665,025,647.51 at the end of 2022, reflecting a decrease of 7.9%[14] - The total liabilities decreased to CNY 361,301,072.89 from CNY 403,249,280.19, a reduction of 10.4%[15] - The equity attributable to shareholders of the parent company was CNY 1,137,468,983.71, slightly down from CNY 1,140,333,568.51[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 32,356[8] - The largest shareholder, Shanghai Haoyuan Venture Investment Development Co., Ltd., held 35.12% of the shares[8] Investment Income - Non-recurring gains and losses totaled ¥3,052,426.34, with significant contributions from government subsidies and investment management gains[6] - The company reported an increase in net profit due to higher investment income recognized under the equity method[6] - The company reported a significant increase in investment income to CNY 2,832,581.91 from CNY 1,880,868.79, marking a rise of 50.7%[19] Revenue and Costs - Total operating costs for Q1 2023 were CNY 61,195,825.19, down 16.1% from CNY 72,908,621.76 in Q1 2022[19] - The company reported a total revenue from sales of goods and services of CNY 62,861,217.44 in Q1 2023, compared to CNY 44,085,140.12 in Q1 2022, reflecting an increase of approximately 42.6%[21]